Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003619 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
A Phase 1 study of Leukemia and Myelodysplastic Syndromes, sponsored by Drexel University College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
NCT00003619 is a Phase 1 study of Leukemia and Myelodysplastic Syndromes that has completed, run by Drexel University College of Medicine. The trial reports 2 study locations across 1 state.
The verdict
NCT00003619, a Phase 1 study of Leukemia and Myelodysplastic Syndromes, has completed, sponsored by Drexel University College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Isotretinoin may help cancer cells develop into normal white blood cells. PURPOSE: Phase I/II trial of topotecan, fludarabine, cytarabine, and filgrastim followed by peripheral stem cell transplantation or isotretinoin in treating patients who have acute myeloid leukemia, myelodysplastic syndrome, or recurrent or refractory acute lymphocytic leukemia.
Conditions Studied
Interventions
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG cytarabine
- DRUG busulfan
- DIETARY_SUPPLEMENT vitamin E
Study Locations (2)
Pennsylvania
- Medical College of Pennsylvania Hospital - Philadelphia
- Medical College of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-02 |
| Est. Completion | 2004-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003619
The ClinicalTrials.gov registry entry for NCT00003619 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Drexel University College of Medicine, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which etoposide is the first listed.
NCT00003619 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00003619 about?
NCT00003619 is a clinical study titled "Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Isotretinoin may help cancer cells develop into no...
What is the current status of trial NCT00003619?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-02. Estimated completion is 2004-04.
What conditions does trial NCT00003619 study?
This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndromes, Thrombocytopenia, Chronic Myeloproliferative Disorders.
What interventions are being tested in trial NCT00003619?
The interventions under investigation include: etoposide (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG), busulfan (DRUG), vitamin E (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00003619?
This trial is sponsored by Drexel University College of Medicine, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003619 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.